Abstract
This study reports that the affinity of HERG1 A for dofetilide is decreased from 0.125 ± 0.003 μM for wild-type (WT) channels to 15 ± 3 μM for F656V, a mutation in the COOH-terminal half of the S6. Similarly, the IC50 for quinidine was increased from 8 ± 4 μM for WT to 219 ± 65 μM for the F656V mutation, whereas affinity for external tetraethylammonium was similar for WT (51 ± 10 mM) and F656V (36 ± 10 mM, NS). Kinetics of onset of inactivation of F656V was similar to WT but kinetics of deactivation, activation, and recovery from inactivation differed from WT. However, mutations in nearby amino acids in the S6 more strikingly altered deactivation, activation, and recovery from inactivation but had little effect on affinity for dofetilide. To assess the effects of disruption of inactivation, the S631A mutation was made. The S631A mutation altered the IC50 for dofetilide to 20 ± 3 μM, but the IC50 for quinidine was unchanged at 8 ± 4 μM for WT and 10 ± 1 μM for S631A. To address whether the F656V mutation alters the IC50 for dofetilide in a channel that does not inactivate, the double mutation S631A/F656V was made. The IC50 for dofetilide of the double mutation was 32 ± 3 μM, which is not substantially different than that of S631A. These data support the notion that allosteric changes occurring during the process of inactivation are necessary for high-affinity dofetilide binding. In conclusion, the Phe-656 residue of HERG is a molecular determinant of high-affinity dofetilide binding.
Footnotes
-
Send reprint requests to: H. J. Duff, M.D., F.R.C.P.(C), Department of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, Alberta, Canada T2N 4N1. E-mail:hduff{at}ucalgary.ca
-
This work was supported by Medical Research Council of Canada, the Heart and Stroke Foundation of Alberta, and the Andrews Family Professorship in Cardiovascular Medicine.
- Abbreviations:
- EAG
- ether a-go-go
- WT
- wild type
- TEA
- tetraethylammonium
- TEAe
- external TEA
- 4-AP
- 4-aminopyridine
- TEAe
- tetraethylammonium external
- Received July 28, 1999.
- Accepted November 9, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|